• Precision medicine, AI among top healthcare investment trends for 2020
• Predictive Oncology is data, AI-driven precision medicine company with an exclusive database of patient samples
• Market estimates for precision medicine expected to reach $84.6 billion by 2024

Precision medicine and artificial intelligence rank high on the list of top investment-focused healthcare trends, according to a recent Emagine article (http://nnw.fm/jKVt0). Both are key areas of focus for Predictive Oncology Inc. (NASDAQ: POAI), a leading data and artificial-intelligence-driven precision medicine company. In an arena where data is king and artificial intelligence is increasingly gravitating to the spotlight, POAI is uniquely positioned with its historic database of patient samples and its cutting-edge AI-powered platform.

“We’ll see more progress in the next 10 years than we’ve seen in the past 50,” stated industry analyst Bill Gadless, who compiled the list of industry trends after attending the 38th annual J.P. Morgan Healthcare Conference. Gadless noted that the hot trends focus on “continuing to save, extend and improve lives.”

The annual conference, the largest and most informative healthcare investment symposium in the industry, brings together industry leaders, innovative technology creators, emerging fast-growth companies and other members of the investment community. Precision medicine received significant interest with its focus on matching up patients with precisely targeted treatments tailored to their unique genetic makeup. At the same time, AI was highlighted as an emerging and increasingly significant tool for use in clinical trials, practice management and digital-health diagnostics.

Emerging as one to watch in the industry, Predictive Oncology is bringing its cutting-edge technology to help pharmaceutical, diagnostic and biotech companies develop new therapies. Through its subsidiary Helomics, a leader in AI and functional precision medicine, POAI harnesses rich patient information gleaned from its PDx tumor profiling platform with the potential to revolutionize cancer research as it is seen today. Through the development of AI-driven predictive models that indicate how tumors respond to drugs, POAI will support clinicians in making decisions to individualize patient treatment. Additionally, these AI-driven models, together with the PDx tumor profiling platform can accelerate research into new targeted therapies.

Drug development for cancer treatment is a costly and time-intensive endeavor – the average drug takes upwards of 10 years and $3 billion to produce – and as technology plays an ever-increasing role in driving medicine, researchers and clinicians are discovering the significant potential of patient-derived PDx models in understanding the activity of potential new drugs on tumors. These models harness cancer cells from patient tumors to create a truly patient-centric future of precision medicine.

As a striking example of this intersection of research and technology, POAI’s Helomics clinical PDx platform compares the drug response and genomic profile of a patient’s own tumor grown in the lab with its database of over 150,000 existing tumor profiles to help recommend the best treatment for that patient. As additional patient samples are tested, they continue to enhance the database improving the recommendations. Leveraging the rich data in this database with AI to create AI-driven predictive models provides a valuable tool for pharmaceutical companies and researchers, offering a model that embodies actual drug response of cancer patients’ individual tumors and their outcomes (i.e. survival). This ability to build AI-driven predictive models of cancer puts the company in a powerful position to offer actionable insights to pharmaceutical companies much more quickly than its competitors.

According to Mordor Intelligence Inc., oncology is expected to have the largest share of the precision medicine market in excess of 30% over other segments, along with a CAGR of 10.3% from 2018 to 2024 (http://nnw.fm/aLp0V). Eyeing the projected overall market estimate of $84.6 billion by 2024, POAI is positioning itself to capture a considerable portion of this growth potential with its unique proprietary technology.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.